Trademark: 87603889
Word
KOBIOLABS
Status
Registered
Status Code
700
Status Date
Tuesday, July 2, 2019
Serial Number
87603889
Registration Number
5791315
Registration Date
Tuesday, July 2, 2019
Mark Type
3
Filing Date
Monday, September 11, 2017
Published for Opposition
Tuesday, April 16, 2019

Trademark Owner History
KoBioLabs, Inc. - Original Registrant

Classifications
5 Pharmaceutical and veterinary preparations, namely, preparations for the prevention of inflammatory bowel disease, irritable bowel syndrome, constipation, diarrhea, metabolic syndrome, obesity, diabetes, hypertension, insulin resistance, high blood cholesterol, high blood Triglycerides, cardiovascular disease, autoimmune disease, atopic dermatitis, arthritis, asthma, allergy, Crohn's disease, mental diseases, neurodegenerative disease, cancer, infectious disease, liver disease and inflammatory disease; Microorganism preparations, namely, nutritive substances for microorganisms for medical or veterinary purposes; Microorganism preparations, namely, microorganism cells for medical or veterinary purposes; Cultures of microorganisms for medical purposes; Biological preparations for medical or veterinary purposes, namely, preparations for the treatment of inflammatory bowel disease, irritable bowel syndrome, constipation, diarrhea, metabolic syndrome, obesity, diabetes, hypertension, insulin resistance, high blood cholesterol, high blood Triglycerides, cardiovascular disease, autoimmune disease, atopic dermatitis, arthritis, asthma, allergy, Crohn's disease, mental diseases, neurodegenerative disease, cancer, infectious disease, liver disease and inflammatory disease; Dietetic food supplements; Dietetic foods adapted for medical purposes; Nutraceuticals for medical purposes, namely, for the treatment of inflammatory bowel disease, irritable bowel syndrome, constipation, diarrhea, metabolic syndrome, obesity, diabetes, hypertension, insulin resistance, high blood cholesterol, high blood Triglycerides, cardiovascular disease, autoimmune disease, atopic dermatitis, arthritis, asthma, allergy, Crohn's disease, mental diseases, neurodegenerative disease, cancer, infectious disease, liver disease and inflammatory disease
44 Performing diagnosis of diseases; Provision of genetic testing for medical treatment purposes; Provision of gene therapy for medical treatment purposes; DNA screening for medical purposes; Consultation and providing information in the fields of medicine and health
42 Consultation in the field of health risk assessment, namely, predicting health risks of individuals with regard to medical disease; Drug discovery services; Provision of scientific information and advice in the field of microorganisms; DNA testing for scientific research purposes; DNA analysis for scientific research purposes; DNA sequencing analysis for scientific research purposes; consultation and providing information in the fields of biomedicine for scientific and research purposes; Consultancy in analysis of biology sequence processing for medical research purposes; Consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; Consultation and providing information in the fields of and pharmacology
The mark consists of the word "KOBIOLABS" in block lettering with the "KO" in the color yellow-green and the "BIOLABS" in the color gray. To the left of the word "KOBIOLABS" is a circular design shaded gray on the interior edges of the circle and transitioning to white towards the circle's interior. A green leaf is positioned in the center of the circle. The rest of the white represents background and is not part of the mark. All other white and gray in the mark represents background and shading areas and is not part of the mark.
The colors white, gray, green and yellow-green are claimed as a feature of the mark.

Trademark Events
Sep 15, 2017
New Application Office Supplied Data Entered
Sep 14, 2017
New Application Entered
Sep 16, 2017
Notice Of Design Search Code E-Mailed
Dec 14, 2017
Assigned To Examiner
Dec 18, 2017
Examiners Amendment -Written
Dec 18, 2017
Examiners Amendment E-Mailed
Dec 18, 2017
Notification Of Examiners Amendment E-Mailed
Dec 18, 2017
Examiner's Amendment Entered
Dec 21, 2017
Non-Final Action Written
Dec 21, 2017
Non-Final Action E-Mailed
Dec 21, 2017
Notification Of Non-Final Action E-Mailed
Jun 8, 2018
Teas Response To Office Action Received
Jun 19, 2018
Examiners Amendment E-Mailed
Jun 8, 2018
Correspondence Received In Law Office
Jun 9, 2018
Teas/Email Correspondence Entered
Jun 19, 2018
Examiners Amendment -Written
Jun 19, 2018
Notification Of Examiners Amendment E-Mailed
Jun 19, 2018
Examiner's Amendment Entered
Sep 5, 2018
Non-Final Action Written
Sep 5, 2018
Non-Final Action E-Mailed
Sep 5, 2018
Notification Of Non-Final Action E-Mailed
Feb 25, 2019
Teas Response To Office Action Received
Feb 25, 2019
Correspondence Received In Law Office
Feb 26, 2019
Teas/Email Correspondence Entered
Feb 28, 2019
Approved For Pub - Principal Register
Mar 27, 2019
Notification Of Notice Of Publication E-Mailed
Apr 16, 2019
Published For Opposition
Apr 16, 2019
Official Gazette Publication Confirmation E-Mailed
Jul 2, 2019
Registered-Principal Register
Jul 2, 2024
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
May 10, 2019
Teas Change Of Correspondence Received

Trademark Alertz updated from USPTO on 2030-01-24